Search

The present aimed to develop a hormonal therapy based on the insertion of a progesterone (P4) insert (PI) during 10 d plus an estradiol injection (E2) at PI removal before the onset of breeding of beef heifers. In Exp. 1, the plasma P4 profile of prepubertal heifers showed that the insertion of a PI or 24 d previously used P4 insert (UPI) sustained plasma P4 above 1 ng/mL for at least the first 7 d of the treatment. In Exp. 2 there was no positive effect of additional estradiol benzoate (EB) administered at the insertion of UPI on the proportion of heifers with a corpus luteum (CL/Treated) 30 d after UPI removal [UPI + EB = 85.3%(a) (n = 134); EB + UPI + EB = 80.8%(a) (n = 125)]; however, both were greater (P < 0.0001) than the Control group [60.3%(b) (n = 129)]. In Exp. 3, a positive effect (P=0.01) of UPI treatment and both E2 supplementations [EB and estradiol cypionate (EC); P = 0.10] at the UPI removal was observed on CL/Treated [Control = 42.5%(b) (n = 94); UPI = 58.5%(a) (n= 130); UPI + EB = 64.0%(a) (n = 128); UPI + EC = 67.2%(a) (n = 128)]. However, greater pregnancy per treated heifer (P/Treated) following artificial insemination (AI) upon estrus detection was achieved when EC was applied [Control = 20.2%(b); UPI = 29.2%(ab); UPI + EB = 26.6%(b); UPI + EC = 36.7%(a)]. In Exp. 4, the treatment prior to the timed AI (TAI) tended to improve pregnancy per TAI [P/AI; Control 43.6% (n = 298) vs. UPI+EC 51.9% (n = 342); P = 0.08], but increased P/Treated [26.5% vs. 43.3%; P < 0.001]. Thus, UPI + EC treatment were efficient in increasing the CL/Treated, tended to improve the P/AI and consequently enhanced P/Treated of zebu beef heifers., (Copyright © 2015 Elsevier B.V. All rights reserved.)

The hypotheses of this study were (1) that the administration of 400IU eCG in a TAI protocol would increase ovarian follicular growth and diameter of the largest follicle (LF), volume of the CL, and produce an earlier rise on serum concentration of progesterone (P4) to ultimately improve P/AI compared to non-treated high-producing Holstein cows; and (2) that 600IU of eCG could enhance any potential effects of a greater gonadotropin treatment upon follicular and luteal size and function, improving P/AI. Cows were subjected to a protocol of synchronization of ovulation for timed artificial insemination (TAI): D0-P4 device insert and estradiol benzoate, D8-P4 device removal and PGF2α; Experiment 1, D10PM - GnRH plus TAI; and Experiment 2, D10AM - GnRH, D10PM - TAI. In Experiment 1, at P4 device removal, cows were assigned to one of the two treatments to receive none (n=232) or 400IU (n=232) of eCG. In Experiment 2, again at P4 device removal, cows were assigned to one of the three treatments to receive no eCG, (n=166) 400 (n=145) or 600IU (n=145) of eCG. Pregnancy was diagnosed 35 days after TAI. Ultrasonographic examination of both ovaries was done in a subset of cows in Experiments 1 [no eCG (n=27) and 400IU eCG (n=14)], and 2 [no eCG (n=15), 400IU eCG (n=14) and 600IU eCG (n=11)]. Exams were conducted at device removal (D8) and TAI (D10) to measure the diameter of the LF; then twice daily from D10 to 13, to determine time to ovulation and the maximum diameter of the LF; and then 3 (D14), 6 (D17), 9 (D20) and 12 (D23) days after presumed ovulation, concurrent with blood sampling, to measure the volume of the CL and serum concentration of P4. In both studies, eCG (400 or 600IU)-treated cows had similar diameter of the LF on D8 and D10, growth rate of the LF from Days 8 to 10, ovulation rate, time to ovulation, volume of the CL, serum concentration of P4 and P/AI as compared to control animals. Thus, adding either 400 or 600IU eCG to TAI protocols was inefficient to alter follicular and luteal dynamics and increase P/AI in high-producing dairy cows under the conditions of these experiments. The lack of positive effects of eCG in the present study might be explained by the small percentage of cows with poor body condition score and lesser incidence of anestrus., (Copyright © 2013 Elsevier B.V. All rights reserved.)

The objectives of this study were to determine the interval from ovulation to deviation and the diameter of the dominant (DF) and largest subordinate (SF) follicles at deviation in buffalo (Bubalus bubalis) heifers. Two methods of evaluation (observed vs. calculated) were used. FSH and LH profiles encompassing follicle deviation (Experiment 1), and the follicular diameter when the DF acquired ovulatory capacity (Experiment 2) were also determined. The time of deviation and the diameter of the DF and the largest SF at deviation did not differ between observed and calculated methods. Overall, follicle deviation occurred 2.6 ± 0.2d (mean ± SEM) after ovulation, and the diameters of the DF and SF at deviation were 7.2 ± 0.2 and 6.4 ± 0.2mm, respectively. No changes in plasma levels of FSH or LH were observed (P=0.32 and P=0.96, respectively). Experiment 2 was conducted in two phases according to the diameter of the DF during the first wave of follicular development at the time of LH challenge (25mg of pLH). In the first phase, follicles ranging from 5.0 to 6.0mm (n=7), 6.1 to 7.0mm (n=11), or 7.1 to 8.0mm (n=9) were used, and in the second phase, follicles ranging from 7.0 to 8.4mm (n=10), 8.5 to 10.0mm (n=10), or 10.1 to 12.0mm (n=9) of diameter were used. After the pLH treatment, the DF was monitored by ultrasonography every 12h for 48h. No ovulations occurred in heifers in the first phase. However, in the second phase, an effect of follicular diameter was observed on ovulation rate [7.0-8.4mm (0.0%, 0/10), 8.5-10.0mm (50.0%, 5/10), and 10.0-12.0mm (55.6%, 5/9)]. In summary, follicle deviation occurred 2.6d after ovulation in buffalo (B. bubalis) heifers, when the diameters of the DF and SF were 7.2 and 6.4mm, respectively. No significant changes in plasma concentrations of FSH or LH were detected. Finally, the acquisition of ovulatory capacity occurred when the DF reached 8.5mm in diameter., (Copyright © 2010 Elsevier B.V. All rights reserved.)

The aim of the present study was to compare a synchronization of time of ovulation protocol for fixed-timed embryo transfer (FTET) with the usual administration of a single dose of prostaglandin associated with detection of estrus. Also, the effect of the presence of CL at the beginning of FTET protocol was evaluated. Lactating Holstein cows (n=651) with three previous artificial inseminations were classified according to presence or absence of a corpus luteum (CL). Cows with a CL were randomly assigned to two additional treatments and submitted to embryo transfer after detection of estrus (PGF-Estrus) or FTET (FTET-CL). Cows without CL were allocated to the FTET-NoCL treatment. On a random day of the estrous cycle (Day 0), cows in the PGF-Estrus treatment (n=229) were treated with 150 microg d-cloprostenol (PGF) i.m. followed by detection of estrus from Day 1 through Day 5 after PGF. Embryos were transferred 6-8 days after estrus detection. Cows in the FTET-CL (n=208; presence of CL) and FTET-NoCL (n=214; absence of CL) treatments received a norgestomet ear implant plus 2mg estradiol benzoate (EB) and 50mg progesterone i.m. on Day 0. On Day 8, the implant was removed and 400 IUeCG, 150 microg d-cloprostenol and 1mg estradiol cypionate i.m. were administered. No detection of estrus was performed and Day 10 was arbitrarily considered as the estrus day. Ultrasonographic exams were performed in all recipients and only cows with a single CL> or =15 mm or multiple CL received a fresh or frozen-thawed embryo on Day 17. Pregnancy was diagnosed by ultrasonography at 30 and 60 days of pregnancy. When FTET and PGF-Estrus were compared, the proportion of cows receiving an embryo (recipients transferred-to-treated rate) was greater in the FTET-CL (75.0% (156/208) than in PGF-Estrus (34.5%, 79/229; P<0.0001) treatment. Pregnancy rate (60 days) was also greater in FTET-CL (29.3%, 61/208) when compared to PGF-Estrus (16.2%, 37/229; P=0.001). However, no differences were found in pregnancy loss [PGF-Estrus=11.9% (5/42), FTET-CL=9.0% (6/67); P=0.62] and circulating progesterone concentration at embryo transfer [PGF-Estrus=4.02+/-0.52 ng/mL (n=25), FTET-CL=3.33+/-0.32 ng/mL (n=27); P=0.25] among these treatments. The presence of CL at the beginning of FTET protocol resulted greater transferred-to-treated rate [FTET-CL=75.0% (156/208) vs. FTET-NoCL=61.2% (131/214); P=0.003], but showed no effect on pregnancy rate at 60 days [FTET-CL=29.3% (61/208) vs. FTET-NoCL=22.9% (49/214); P=0.13], pregnancy loss [FTET-CL=9.0% (6/67) vs. FTET-NoCL=2.0% (1/50); P=0.15] and circulating progesterone concentration at ET [FTET-CL=3.33+/-0.32 ng/mL (n=27) compared to FTET-NoCL=3.44+/-0.40 ng/mL (n=2 9); P=0.82]. In conclusion, the protocol for synchronization of time of ovulation using norgestomet ear implant, EB and eCG increased recipients transferred-to-treated and pregnancy rates in high-producing repeat-breeder Holstein cows. Also, recipients without CL at the beginning of the time of ovulation synchronization treatment resulted in similar pregnancy rate as recipients with CL submitted to FTET protocol. Thus, the suggested protocol allowed the performance of FTET, without the need for detection of estrus, simplifying the reproductive management and increasing the reproductive efficiency in repeat-breeder Holstein recipients., (Copyright 2009 Elsevier B.V. All rights reserved.)

A total of 177 Nelore heifers were examined by ultrasonography to determine the presence or absence of a corpus luteum (CL) and received a 3mg norgestomet ear implant plus 2mg of estradiol benzoate i.m. On Day 8, implants were removed and 150 microg of d-cloprostenol i.m. was administered. At the time of norgestomet implant removal, heifers with or without CL at the time of initiating treatment were assigned equally and by replicate to be treated with 0IU (n=87) or 400IU (n=90) eCG i.m. All heifers received 1mg of EB i.m. on Day 9 and were submitted to fixed-time artificial insemination (FTAI) 30-34h later. The addition of eCG increased the diameter of the largest follicle (LF) at FTAI (10.6+/-0.2mm vs. 9.5+/-0.2mm; P=0.003; mean+/-SEM), the final growth rate of the LF (1.14+/-0.1mm/day vs. 0.64+/-0.1mm/day; P=0.0009), ovulation rate [94.4% (85/90) vs. 73.6% (64/87); P=0.0006], the diameter of the CL at Day 15 (15.5+/-0.3mm vs. 13.8+/-0.3mm; P=0.0002), serum concentrations of progesterone 5 days after FTAI (6.6+/-1.0 ng/ml vs. 3.6+/-0.7ng/ml; P=0.0009), and pregnancy per AI [P/AI; 50.0% (45/90) vs. 36.8% (32/87); P=0.04]. The absence of a CL at the beginning of the treatment negatively influenced the P/AI [30.2% (16/53) vs. 49.2% (61/124); P=0.01]. Therefore, the presence of a CL (and/or onset of puberty) must be considered in setting up FTAI programs in heifers. In addition, eCG may be an important tool for the enhancement of follicular growth, ovulation, size and function of the subsequent CL, and pregnancy rates in progestin-based FTAI protocols in Bos indicus heifers., (Copyright 2009 Elsevier B.V. All rights reserved.)

The present study investigated how the timing of the administration of estradiol benzoate (EB) impacted the synchronization of ovulation in fixed-time artificial insemination protocols of cattle. To accomplish this, two experiments were conducted, with EB injection occurring at different times: at withdrawal of the progesterone-releasing (P4) intravaginal device or 24h later. The effectiveness of these times was compared by examining ovarian follicular dynamics (Experiment 1, n=30) and conception rates (Experiment 2, n=504). In Experiment 1, follicular dynamics was performed in 30 Nelore cows (Bos indicus) allocated into two groups. On a random day of the estrous cycle (Day 0), both groups received 2mg of EB i.m. and a P4-releasing intravaginal device, which was removed on Day 8, when 400 IU of eCG and 150 microg of PGF were administered. The control group (G-EB9; n=15) received 1mg of EB on Day 9, while Group EB8 (G-EB8; n=15) received the same dose a day earlier. Ovarian ultrasonographic evaluations were performed every 8h after device removal until ovulation. The timing of EB administration (Day 8 compared with Day 9) did affect the interval between P4 device removal to ovulation (59.4+/-2.0 h compared with 69.3+/-1.7h) and maximum diameter of dominant (1.54+/-0.06 acm compared with 1.71+/-0.05 bcm, P=0.03) and ovulatory (1.46+/-0.05 acm compared with 1.58+/-0.04 bcm, P<0.01) follicles. In Experiment 2, 504 suckling cows received the same treatment described in Experiment 1, but insemination was performed as follows: Group EB8-AI48 h (G-EB8-AI48 h; n=119) and Group EB8-AI54 h (G-EB8-AI54 h; n=134) received 1mg of EB on Day 8 and FTAI was performed, respectively, 48 or 54 h after P4 device removal. Group EB9-AI48h (G-EB9-AI48 h; n=126) and Group EB9-AI54 h (G-EB9-AI54 h; n=125) received the same treatments and underwent the same FTAI protocols as G-EB8-AI48 h and G-EB8-AI54 h, respectively; however, EB was administered on Day 9. Conception rates were greater (P<0.05) in G-EB9-AI54 h [63.2% (79/125) a], G-EB9-AI48 h [58.7% (74/126) a] and G-EB8-AI48 h [58.8% (70/119) a] than in G-EB8-AI54 h [34.3% (46/134) b]. We concluded that when EB administration occurred at device withdrawal (D8), the interval to ovulation shortened and dominant and ovulatory follicle diameters decreased. Furthermore, when EB treatment was performed 24h after device removal, FTAI conducted at either 48 or 54 h resulted in similar conception rates. However, EB treatment on the same day as device withdrawal resulted in a lesser conception rate when FTAI was conducted 54 h after device removal.